Cargando…
Targeting glutaminase1 and synergizing with clinical drugs achieved more promising antitumor activity on multiple myeloma
Multiple myeloma (MM) pathogenesis remains incompletely understood and biomarkers predicting treatment response still remain lacking. Here we describe the rational mechanisms of combining targeting glautaminase1 (GLS1) with other chemo-reagents for MM treatment. Gls1 is highly expressed cMYC/KRAS12V...
Autores principales: | Qiu, Qiang, Li, Mengyuan, Yang, Linyu, Tang, Minghai, Zheng, Li, Wang, Fang, Qiu, Huandi, Liang, Cailing, Li, Ning, Yi, Dongni, Yi, Yuyao, Pan, Cong, Yang, Shengyong, Chen, Lijuan, Hu, Yiguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800263/ https://www.ncbi.nlm.nih.gov/pubmed/31666930 http://dx.doi.org/10.18632/oncotarget.27243 |
Ejemplares similares
-
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017) -
HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells
por: Qiu, Qiang, et al.
Publicado: (2022) -
Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation
por: Effenberger, Madlen, et al.
Publicado: (2017) -
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN
por: Qiu, Qiang, et al.
Publicado: (2023) -
The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells
por: Wang, Diancheng, et al.
Publicado: (2016)